Visit the NanoSight web site
Click on the advert above to visit the company web site

Product category: Data management software
News Release from: CLC bio
Edited by the Laboratorytalk Editorial Team on 19 December 2007

Bioinformatics for vaccine target
development

Note: A free brochure or catalogue is available from CLC bio about its services. Click here to request a copy.

Ace BioSciences, an emerging pharma company developing novel protein-based vaccines and antibodies to address infectious diseases, and CLC bio announce a collaborative bioinformatics agreement

Ingelise Saunders, chief executive officer at Ace BioSciences said: "At Ace BioSciences we place considerable emphasis on selecting partners based on their scientific know-how - and in that regard we recognise CLC bio as the leading company within bioinformatics, with a global reputation and internationally renowned experts "We see this collaboration as a significant opportunity to augment and expand our bioinformatics platform to increase efficiency, enhance our analyses, and accelerate our research"

Jannick Bendtsen, project manager and senior scientific officer at CLC bio commented: "We are looking forward to this collaboration, which is scientifically interesting and challenging.

"The implementation of our customised software will streamline and fast-track analysis and further increase statistical confidence in the selection of novel candidates for inclusion in the Ace BioSciences development portfolio.

"Implementation of automated target validation protocols will increase efficiency and the rate of data throughput, improve quality assurance and enhance data security".

CLC bio will upgrade and expand Ace BioSciences's existing bioinformatics platform to ensure the company is taking advantage of the most up-to-date, relevant, and innovative software, including state-of-the-art protein vaccine target characterisation.

In addition, CLC bio will provide greater integration and cross-referencing capabilities, securing for Ace BioSciences the ability to apply more extensive statistical analyses to its databases and laboratory information.

CLC bio's customised approach will strengthen Ace BioSciences's ability to compare, rank, and prioritise potential vaccine targets.

It consists of a number of CLC workbenches for DNA, RNA, and protein sequence analysis, supplemented with customised bioinformatics modules that are proprietary for Ace BioSciences. Request free introductory details about products from CLC bio ...

CLC bio: contact details and other news
Email this article to a colleague
Register for the free Laboratorytalk email newsletter
Laboratorytalk Home Page

Search the Pro-Talk network of sites

Visit the NanoSight web site